



# The first FDA-approved MASH treatment is *well within reach.*



**~8 million** patients living with F2-F3 MASH in the U.S., but **~90%** are undiagnosed.<sup>1</sup>

## Give patients living with MASH the latest treatment, and total medication management.

AllianceRx Walgreens Pharmacy now has access to the first FDA-approved treatment indicated in conjunction with diet and exercise for the treatment of adults with MASH (metabolic dysfunction-associated steatohepatitis) also known as NASH (noncirrhotic nonalcoholic steatohepatitis) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Walgreens can provide your patients with convenient access to this new therapy and help manage their other prescriptions—providing specialized, holistic care for the whole patient.



### Whole-Person Care

Walgreens takes a holistic approach to help manage all the medications and conditions of MASH patients, including diabetes and obesity as well as nutrition and exercise counseling.



### Walgreens Connected Care<sup>®</sup> MASH

A high-touch management program helps support therapy with monitoring, consultations, education and clinical interventions when necessary.



### Financial Assistance Coordination

Walgreens helped secure \$608M in financial assistance for eligible patients in 2023.<sup>2</sup>

To learn more, contact your Walgreens specialty pharmacy representative.



<sup>1</sup>Estimate of total 2022 U.S. NASH F2-F3 population. Source: Fishman J et al. ISPOR Europe. 2022

<sup>2</sup>Source: Combined data across all disease states for Walgreens specialty pharmacy and AllianceRx Walgreens Pharmacy, 2023.